Is N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide? Is N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide safe for nursing mother and child? Does N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide extracts into breast milk? Does N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide has any long term or short term side effects on infants? Can N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide influence milk supply or can N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide decrease milk supply in lactating mothers?

N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Because there is little published experience with N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide during breastfeeding and excretion into breastmilk is higher than with other pharmacologically similar drugs, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.[1] Some reviewers consider N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide to be contraindicated during breastfeeding.[2]

A 13-month-old infant was partially breastfed by a mother who was taking N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide 400 mg, fluvoxamine 200 mg, and azathioprine 150 mg daily, and was using nicotine chewing gum for smoking cessation. The mother had been taking N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide for 9 days; the duration of the other medications was not stated. A pediatric examination found the infant to be developing well.[4] A woman with long-standing schizophrenia was treated with N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide 400 mg and haloperidol 5 mg daily throughout most of her pregnancy and during breastfeeding (extent not stated). Follow-up of the breastfed infant for 13 months by a pediatrician found no adverse effects and normal development of the infant.[6]

N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide increases serum prolactin and may cause galactorrhea at a higher rate than other psychotropic drugs.[7][8][9][10][11][12] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.